Technical Analysis for MNTA - Momenta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 10.095 3.75% 0.37
MNTA closed down 5.26 percent on Wednesday, July 17, 2019, on 1.89 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Aug 7

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MNTA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 3.75%
Lower Bollinger Band Walk Weakness 3.75%
Multiple of Ten Bearish Other 3.75%
Below Lower BB Weakness 3.75%
Down 3 Days in a Row Weakness 3.75%
Lower Bollinger Band Touch Weakness 3.75%
Oversold Stochastic Weakness 3.75%
New 52 Week Closing Low Bearish -1.70%
Lower Bollinger Band Walk Weakness -1.70%
Below Lower BB Weakness -1.70%

Older signals for MNTA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules. Its complex molecules include polysaccharides, polypeptides, and proteins and antibodies. The company's complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for autoimmune and inflammatory diseases; M834 for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company's novel products comprise M402, a novel heparan sulfate mimetic that binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis; and the sialylation technology, which is a discovery program that is intended to modify immunoglobulin G antibodies in intravenous immunoglobulin, a drug to treat autoimmune and inflammatory diseases. It has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Immunology Antibodies Immune System Tumor Antibody Monoclonal Antibody Autoimmunity Autoimmune And Inflammatory Diseases Glycoproteins Biosimilar Metastasis Deep Vein Thrombosis Relapsing Remitting Multiple Sclerosis Acute Coronary Syndromes Immunoglobulin Therapy
Is MNTA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.2
52 Week Low 9.55
Average Volume 437,701
200-Day Moving Average 13.2768
50-Day Moving Average 12.293
20-Day Moving Average 11.743
10-Day Moving Average 11.233
Average True Range 0.5312
ADX 24.69
+DI 11.2823
-DI 39.2871
Chandelier Exit (Long, 3 ATRs ) 11.6364
Chandelier Exit (Short, 3 ATRs ) 11.203599999999999
Upper Bollinger Band 13.362
Lower Bollinger Band 10.124
Percent B (%b) -0.12
BandWidth 27.573874
MACD Line -0.5527
MACD Signal Line -0.3417
MACD Histogram -0.211
Fundamentals Value
Market Cap 718.01 Million
Num Shares 73.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -15.20
Price-to-Sales 9.20
Price-to-Book 2.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.75
Resistance 3 (R3) 10.82 10.56 10.58
Resistance 2 (R2) 10.56 10.30 10.52 10.52
Resistance 1 (R1) 10.14 10.14 10.01 10.07 10.47
Pivot Point 9.88 9.88 9.81 9.84 9.88
Support 1 (S1) 9.46 9.62 9.33 9.39 8.99
Support 2 (S2) 9.20 9.46 9.16 8.94
Support 3 (S3) 8.78 9.20 8.88
Support 4 (S4) 8.71